脊柱转移瘤立体定向体部放疗的疗效与安全性:为制定ESTRO实践指南而进行的系统综述与荟萃分析
该系统综述与荟萃分析纳入2005年1月至2021年9月的69项研究(7236个转移灶、5736例患者),评估脊柱转移瘤SBRT的疗效与安全性;汇总疼痛总缓解率83%、完全缓解率36%、1年局部控制率94%,椎体骨折率9%、放射性脊髓病0%、疼痛 flare 6%,仅1.7%的椎体骨折需手术稳定。
要点
- 脊柱转移瘤SBRT汇总疼痛总缓解率83%、完全缓解率36%、1年局部控制率94%。
- 汇总椎体骨折率9%、放射性脊髓病0%、疼痛flare 6%,仅1.7%的骨折需手术稳定。
- 作者认为脊柱SBRT疗效与安全性良好,对寡转移患者尤其有意义。
核心结论
- 脊柱SBRT具有有利的疗效与安全性特征,可提供持久的疼痛控制和疾病控制,这对寡转移患者尤其有意义。
研究设计与样本
- 采用PRISMA方法学进行系统综述与荟萃分析,纳入2005年1月至2021年9月的文献,例外为2023年4月补充的随机III期试验RTOG-0631,排除再程放疗。
主要发现
- 共分析69项研究,评估5736例患者的7236个转移灶。
- 汇总疼痛总缓解率为83%(95%CI 68%-94%),汇总完全疼痛缓解率为36%(95%CI 20%-53%),1年局部控制率为94%(95%CI 86%-99%),异质性分别为I²=93%、I²=86%、I²=86%。
- 汇总椎体骨折率为9%(95%CI 4%-16%),汇总放射性脊髓病率为0%(95%CI 0-2%),汇总疼痛flare率为6%(95%CI 3%-17%),异质性分别为I²=92%、I²=0%、I²=95%。
- 仅1.7%的椎体骨折需要手术稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 疼痛总缓解率、完全疼痛缓解率、1年局部控制率、椎体骨折率、放射性脊髓病率和疼痛flare率的汇总估计均存在不同程度的异质性(I²分别为93%、86%、86%、92%、0%、95%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Advances in characterizing cancer biology and the growing availability of novel targeted agents and immune therapeutics have significantly changed the prognosis of many patients with metastatic disease. Palliative radiotherapy needs to adapt to these developments. In this study, we summarize the available evidence for stereotactic body radiotherapy (SBRT) in the treatment of spinal metastases. MATERIALS AND METHODS: A systematic review and meta-analysis was performed using PRISMA methodology, including publications from January 2005 to September 2021, with the exception of the randomized phase III trial RTOG-0631 which was added in April 2023. Re-irradiation was excluded. For meta-analysis, a random-effects model was used to pool the data. Heterogeneity was assessed with the I2-test, assuming substantial and considerable as I2 > 50 % and I2 > 75 %, respectively. A p-value < 0.05 was considered statistically significant. RESULTS: A total of 69 studies assessing the outcomes of 7236 metastases in 5736 patients were analyzed. SBRT for spine metastases showed high efficacy, with a pooled overall pain response rate of 83 % (95 % confidence interval [CI] 68 %-94 %), pooled complete pain response of 36 % (95 % CI: 20 %-53 %), and 1-year local control rate of 94 % (95 % CI: 86 %-99 %), although with high levels of heterogeneity among studies (I2 = 93 %, I2 = 86 %, and 86 %, respectively). Furthermore, SBRT was safe, with a pooled vertebral fracture rate of 9 % (95 % CI: 4 %-16 %), pooled radiation induced myelopathy rate of 0 % (95 % CI 0-2 %), and pooled pain flare rate of 6 % (95 % CI: 3 %-17 %), although with mixed levels of heterogeneity among the studies (I2 = 92 %, I2 = 0 %, and 95 %, respectively). Only 1.7 % of vertebral fractures required surgical stabilization. CONCLUSION: Spine SBRT is characterized by a favorable efficacy and safety profile, providing durable results for pain control and disease control, which is particularly relevant for oligometastatic patients.
引用
- Guninski RS, Cuccia F, Alongi F, et al. Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline. Radiother Oncol. 2023. PMID: 37922993. doi:10.1016/j.radonc.2023.109969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。